Mice lacking major brain gangliosides develop Parkinsonism

Neurochemical Research

Volumn 36, Issue 9, 2011, Pages 1706-1714

  Wu, Gusheng ^a   Lu, Zi Hua ^a   Kulkarni, Neil ^a   Amin, Ruchi ^a   Ledeen, Robert W ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Alpha synuclein; Dopaminergic neurons; GM1 ganglioside; LIGA 20; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; CARBIDOPA; DOPAMINE; GANGLIOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOTETRAOSE; LEVODOPA; LIGA 20; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; FEMALE; KNOCKOUT MOUSE; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; SUBSTANTIA NIGRA PARS COMPACTA;

AGED; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; BRAIN CHEMISTRY; FEMALE; GANGLIOSIDES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; NEUROPSYCHOLOGICAL TESTS; PARKINSONIAN DISORDERS; PSYCHOMOTOR PERFORMANCE;

MUS;

EID: 80755189053     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0437-y     Document Type: Article

References (40)

1. Allende ML, Proia RL (2002) Lubricating cell signaling pathways with gangliosides. Current Opinion in Struct Biol 12:587-592 (Pubitemid 35449065)
2. Takamiya K, Yamamoto A, Furukawa K et al (1996) Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Nat Acad Sc USA 93:10662-10667 (Pubitemid 26333045)
3. Sheikh KA, Sun J, Liu Y et al (1999) Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Nat Acad Sci USA 96:7532-7537 (Pubitemid 29299696)
4. Chiavegatto S, Sun J, Nelson RJ et al (2000) A functional role for complex gangliosides: Motor deficits in GM2/GD2 synthase knockout mice. Exp Neurol 166:227-234
5. Wu G, Xie X, Lu Z-H et al (2001) Cerebellar neurons lacking complex gangliosides degenerate in the presence of depolarizing levels of potassium. Proc Natl Acad Sci USA 98:307-312 (Pubitemid 32095905)
6. Wu G, Lu Z-H, Wang J et al (2005) Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: Protection with LIGA 20, a membrane-permeant analog of GM1. J Neurosci 25:11014-11022 (Pubitemid 41692631)
7. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211 (Pubitemid 36007810)
8. Meredith GE, Sonsalla PK, Chesselet M-F (2008) Animal models of Parkinson's disease progression. Acta Neuropathol 115:385-398
9. Hadjiconstantinou M, Rossetti ZL, Paxton RC et al (1986) Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharm 25:1075-1077 (Pubitemid 16050473)
10. Schneider JS, Kean A, DiStefano L (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases DA synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res 42:117-123
11. Schneider JS, DiStefano L (1995) Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: Effects of dose and extent of lesion. Neuropharm 34:489-493
12. Hadjiconstantinou M, Mariani AP, Neff NH (1989) GM1 ganglioside- induced recovery of nigrostriatal dopaminergic neurons after MPTP: An immunohistochemical study. Brain Res 484:297-303 (Pubitemid 19100091)
13. Pope-Coleman A, Schneider JS (1998) Effects of chronic GM1 ganglioside treatment on cognitive and motor deficits in a slowly progressing model of Parkinsonism in non-human primates. Restorative Neurol Neurosci 12:255-266 (Pubitemid 28462059)
14. Schneider JS, Roeltgen DP, Mancall EL (1998) Parkinson's disease: Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 50:1630-1636 (Pubitemid 28283228)
15. Schneider JS, Sendek S, Daskalakis C et al (2010) GM1 ganglioside in Parkinson's disease: Results of a five year open study. J Neurol Sciences 292:45-51
16. Liu Y, Wada R, Kawai H et al (1999) A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 103:497-505 (Pubitemid 29094050)
17. Sedelis M, Hofele K, Auburger GW et al (2000) MPTP susceptibility in the mouse: Behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171-182
18. Lu XH, Fleming SM, Meurers B et al (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 29:1962-1976
19. Prasad K, Richfield EK (2008) Sporadic midbrain dopamine neuron abnormalities in laboratory mice. Neurobiol Disease 32:262-272
20. Prasad K, Richfield EK (2010) Number and nuclear morphology of TH? and TH- neurons in the mouse ventral midbrain using epifluorescence stereology. Exp Neurol 225:328-340
21. Lees M, Paxman S (1972) Lipid composition of the normal human brain: Gray matter, white matter, and myelin. J Lipid Res 6:537-544
22. German DC, Manaye KF, Sonsalla PK, Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: Sparing of calbindin-D28k-containing cells. Ann NY Acad Sci 648:42-62
23. Fahn S (2006) Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 991:1-14
24. Jankovic J (2008) Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psych 79:368-376 (Pubitemid 351441488)
25. Eriksen JL, Dawson TM, Dickson DW et al (2003) Caught in the act: Alpha-synuclein is the culprit in Parkinson's disease. Neuron 40:453-456 (Pubitemid 37494695)
26. Matsuda J, Vanier MT, Popa J et al (2006) GD3- and O-acetylated GD3-gangliosides in the GM2 synthase-deficient mouse brain and their immunohistochemical localization. Proc Jpn Acad Ser B 82:189-196 (Pubitemid 44775228)
27. Manev H, Favaron M, Vicini S et al (1990) Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: Protection by synthetic derivatives of endogenous sphingolipids. J Pharmacol Exp Ther 252:419-427 (Pubitemid 20067745)
28. Wu G, Lu Z-H, Xie X et al (2004) Susceptibility of cerebellar granule neurons from GM2/GD2 synthase-null mice to apoptosis induced by glutamate excitotoxicity and elevated KCl: Rescue by GM1 and LIGA20. Glycoconj J 21:305-313 (Pubitemid 39434559)
29. Schneider JS, DiStefano L (1994) Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism. Neurology 44:748-750 (Pubitemid 24130011)
30. Xie X, Wu G, Lu Z-H et al (2002) Potentiation of a sodiumcalcium exchanger in the nuclear envelope by nuclear GM1 ganglioside. J Neurochem 81:1185-1195 (Pubitemid 34809253)
31. Wu G, Xie X, Lu Z-H et al (2009) Sodium-calcium exchanger complexed with GM1 ganglioside in nuclear membrane transfers calcium from nucleoplasm to endoplasmic reticulum. Proc Natl Acad Sci USA 106:10829-10834
32. Wei J, Fujita M, Nakai M et al (2009) Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Amer J Pathol 174:1891-1909
33. Martinez Z, Zhu M, Han S et al (2007) GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46:1868-1877
34. Chan CS, Gertler TS, Surmeier DJ (2009) Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 32:249-256
35. Okada M, Itoh M, Haraguchi M et al (2002) b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J Biol Chem 277:1633-1636 (Pubitemid 34968730)
36. Handa Y, Ozaki N, Honda T et al (2005) GD3 synthase gene knockout mice exhibit thermal hyperalgesia and mechanical allodynia but decreased response to formalin-induced prolonged noxious stimulation. Pain 117:271-279 (Pubitemid 41383523)
37. Miyagi T, Wada T, Iwamatsu A et al (1999) Molecular cloning and characterization of plasma membrane-associated sialidase specific for gangliosides. J Biol Chem 274:5004-5011
38. Wang J, Wu G, Miyagi T, Lu Z-H, Ledeen RW (2009) Sialidase occurs in both membranes of the nuclear envelope and hydrolyzes endogenous GD1a. J Neurochem 111:547-554
39. Goodwin NS, Engelborghs Y, Pountney DL (2010) Raised calcium promotes a-synuclein aggregate formation. Mol Cell Neurosci (2010 Dec 8) [Epub ahead of print]
40. Yazdani U, German DC, Liang C-L et al (2006) Rat model of Parkinson's disease: Chronic central delivery of 1-methyl-4- phenylpyridinium (MPP?). Exp Neurol 200:172-183 (Pubitemid 44080759)